HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thomas C Heineman Selected Research

Subunit Vaccines

1/2018Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
1/2018Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older.
1/2018Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials.
12/2017Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
12/2017Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.
9/2016Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
2/2016Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults.
10/2015Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
5/2015Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.
12/2013Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Thomas C Heineman Research Topics

Disease

23Herpes Zoster
01/2021 - 05/2011
7Infections
03/2014 - 06/2005
3Postherpetic Neuralgia
01/2019 - 09/2016
3Pain (Aches)
01/2019 - 12/2013
2Injection Site Reaction
01/2019 - 05/2006
2Fatigue
01/2019 - 12/2013
2Neoplasms (Cancer)
01/2019 - 01/2019
2Genital Diseases
03/2014 - 01/2012
2Herpes Genitalis (Genital Herpes)
06/2013 - 01/2012
2Chickenpox
10/2012 - 05/2011
1Multiple Myeloma
11/2021
1Diphtheria
01/2019
1Tetanus
01/2019
1B-Cell Lymphoma (Lymphoma, B Cell)
01/2019
1Pneumonia (Pneumonitis)
11/2014
1Herpes Simplex
01/2012
1Melanoma (Melanoma, Malignant)
05/2011
1Varicella Zoster Virus Infection
05/2011
1Virus Diseases (Viral Diseases)
01/2002

Drug/Important Bio-Agent (IBA)

18VaccinesIBA
11/2021 - 06/2005
12Subunit VaccinesIBA
01/2018 - 01/2012
7Glycoproteins (Glycoprotein)IBA
01/2019 - 02/2007
7Herpes Zoster VaccineIBA
01/2019 - 12/2017
4AS01B adjuvantIBA
01/2018 - 02/2016
4varicella-zoster virus glycoprotein EIBA
01/2018 - 12/2013
2AntibodiesIBA
03/2014 - 01/2012
2Proteins (Proteins, Gene)FDA Link
05/2011 - 02/2007
1insulin receptor-related receptor (IRR)IBA
01/2019
1Pertussis VaccineIBA
01/2019
1Influenza Vaccines (Influenza Vaccine)FDA Link
12/2017
1DNA (Deoxyribonucleic Acid)IBA
03/2013
1Viral DNAIBA
03/2013
1CytokinesIBA
05/2011
1Reactive Oxygen Species (Oxygen Radicals)IBA
05/2011
1InterferonsIBA
05/2011
1InflammasomesIBA
05/2011
1Pyrin Domain-Containing 3 Protein NLR FamilyIBA
05/2011
1Free RadicalsIBA
05/2011
1Amino AcidsFDA Link
01/2002

Therapy/Procedure

1Stem Cell Transplantation
01/2019
1Drug Therapy (Chemotherapy)
01/2019
1Hematopoietic Stem Cell Transplantation
01/2019
1Art Therapy
04/2015